Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Conditions:   Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Stomach;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Ovarian Mucinous Cystadenocarcinoma;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol SpecificInterventions:   Drug: veliparib;   Drug: capecitabine;   Drug: oxaliplatin;   Other: pharmacological study;   Other: laboratory biomarker analysisSponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)Active, not recruiting - verified October 2013
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials